Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

• Published in: The lancet oncology Vol. 19; no. 10; pp. e534 - e545
• Main Authors: Lecouvet, Frédéric E, Oprea-Lager, Daniela E, Liu, Yan, Ost, Piet, Bidaut, Luc, Collette, Laurence, Deroose, Christophe M, Goffin, Karolien, Herrmann, Ken, Hoekstra, Otto S, Kramer, Gem, Lievens, Yolande, Lopci, Egesta, Pasquier, David, Petersen, Lars J, Talbot, Jean-Noël, Zacho, Helle, Tombal, Bertrand, deSouza, Nandita M
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2018; Elsevier Limited; Elsevier
• Subjects: Abdomen; Antigens; Cancer; Cancer therapies; Castration; Choline; Clinical trials; Clinical Trials as Topic - methods; Computed tomography; Consensus; Humans; Life Sciences; Ligands; Magnetic resonance imaging; Male; Metastases; Metastasis; Morbidity; Neoplasm Metastasis; Predictive Value of Tests; Progression-Free Survival; Prostate cancer; Prostatic Neoplasms - diagnostic imaging; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Radiation therapy; Reproducibility of Results; Research Design; Tumors; Urology

Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the...